CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-28 | Hoge Stephen President | Exercise or conversion 10b5-1 | +611 | 1,442,968 | ||
| 2024-08-28 | Hoge Stephen President | Exercise or conversion · Restricted Stock Units 10b5-1 | −611 | 6,105 | ||
| 2024-08-28 | Mock James M Chief Financial Officer | Sale 10b5-1 | −1,321 | $79.39 | $105K | 8,600 |
| 2024-08-28 | Klinger Shannon Thyme Chief Legal Officer | Sale 10b5-1 | −1,319 | $79.39 | $105K | 17,280 |
| 2024-08-27 | Mock James M Chief Financial Officer | Exercise or conversion 10b5-1 | +1,326 | 8,595 | ||
| 2024-08-27 | Mock James M Chief Financial Officer | Exercise or conversion 10b5-1 | +1,326 | 9,921 | ||
| 2024-08-27 | Mock James M Chief Financial Officer | Exercise or conversion · Performance Stock Units 10b5-1 | −1,326 | 2,652 | ||
| 2024-08-27 | Mock James M Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −1,326 | 2,652 | ||
| 2024-08-27 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion 10b5-1 | +2,652 | 18,599 | ||
| 2024-08-27 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −2,652 | 5,305 | ||
| 2024-08-12 | Hoge Stephen President | Sale 10b5-1 | −254 | $84.10 | $21K | 1,442,357 |
| 2024-08-09 | Hoge Stephen President | Exercise or conversion 10b5-1 | +522 | 1,442,611 | ||
| 2024-08-09 | Hoge Stephen President | Exercise or conversion · Restricted Stock Units 10b5-1 | −522 | 1,046 | ||
| 2024-08-05 | Rubenstein David M. Director | Grant or award · Stock Option (Right to Buy) | +5,051 | 5,051 | ||
| 2024-08-05 | Rubenstein David M. Director | Grant or award · Stock Option (Right to Buy) | +4,065 | 4,065 | ||
| 2024-08-05 | Rubenstein David M. Director | Grant or award · Restricted Stock Units | +850 | 850 | ||
| 2024-08-05 | Rubenstein David M. Director | Grant or award · Restricted Stock Units | +677 | 677 | ||
| 2024-07-31 | AFEYAN NOUBAR Director | Sale 10b5-1 | −4,599 | $118.96 | $547K | 2,234,416 |
| 2024-07-31 | AFEYAN NOUBAR Director | Sale 10b5-1 | −5,664 | $119.84 | $679K | 2,228,752 |
| 2024-07-31 | AFEYAN NOUBAR Director | Sale 10b5-1 | −3,428 | $120.88 | $414K | 2,225,324 |
Page 24 of 38 · 743 trades